Literature DB >> 22264575

Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men.

Jennifer G Robinson1, Catherine Rahilly-Tierney, Elizabeth Lawler, J Michael Gaziano.   

Abstract

BACKGROUND: Most incident cardiovascular disease (CVD) occurs after patients reach the age of 65. The additive benefits of aggressive risk factor management with advancing age are not well established.
OBJECTIVE: To evaluate the relationship between control of four modifiable risk factors (smoking, non-high density lipoprotein cholesterol, blood pressure, and aspirin use) and risk of CVD in a primary prevention population of older men.
MATERIALS AND METHODS: U.S. male physicians from the Physicians' Health Study (n = 4182; an epidemiologic follow-up of a randomized trial of aspirin and beta-carotene) who in 1997 were ≥ 65 years, free of CVD and diabetes, and had a blood sample on file were studied. Cox proportional hazard models were adjusted for age and competing causes of death. The first of any CVD event, defined as cardiovascular death, nonfatal myocardial infarction, angina, coronary revascularization, nonfatal stroke, transient ischemic attack, carotid artery surgery, and other peripheral vascular disease surgery, was measured.
RESULTS: Mean follow-up was 9.3 years, mean age was 73 years, and 96% were nonsmokers. Compared with when 4 of 4 risk factors were controlled (6.0% of participants), control of 0 of 4 risk factors almost quadrupled the risk of CVD (0.4% of participants; event rate 41.2%; hazard ratio [HR] 3.83, 95% confidence interval [95% CI] 1.72-8.55); control of 1 of 4 risk factors more than doubled the risk (14.2% of participants; HR 2.53, 95% CI 1.80-3.57); control of 2 of 4 risk factors almost doubled the risk (43.8% of participants; HR 1.94, 95% CI 1.41-2.69), and those with control of 3 of 4 risk factors also were at increased risk (35.6% of participants; HR 1.80, 95% CI 1.30-2.50). Control of each additional risk factor was associated with greater cardiovascular protection (P for trend P = .002). Depending on the number of risk factors controlled, the number-needed to control to prevent one CVD event ranged from 5 to 22.
CONCLUSION: Control of 4 treatable risk factors (nonsmoking, control of non-high density lipoprotein cholesterol and blood pressure, and aspirin use) was associated with substantial protection against incident cardiovascular events in older men even after adjustment for competing causes of mortality.
Copyright © 2012 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22264575      PMCID: PMC3266543          DOI: 10.1016/j.jacl.2011.10.019

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  35 in total

Review 1.  Clinical practice. Isolated systolic hypertension in the elderly.

Authors:  Aram V Chobanian
Journal:  N Engl J Med       Date:  2007-08-23       Impact factor: 91.245

2.  Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage.

Authors:  J Michael McWilliams; Ellen Meara; Alan M Zaslavsky; John Z Ayanian
Journal:  Ann Intern Med       Date:  2009-04-21       Impact factor: 25.391

3.  Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

Authors:  Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-02-23       Impact factor: 29.690

4.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

5.  Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).

Authors:  Prakash Deedwania; Peter H Stone; C Noel Bairey Merz; Juan Cosin-Aguilar; Nevres Koylan; Don Luo; Pamela Ouyang; Ryszard Piotrowicz; Karin Schenck-Gustafsson; Philippe Sellier; James H Stein; Peter L Thompson; Dan Tzivoni
Journal:  Circulation       Date:  2007-02-05       Impact factor: 29.690

6.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

7.  Trends in the prevalence of low risk factor burden for cardiovascular disease among United States adults.

Authors:  Earl S Ford; Chaoyang Li; Guixiang Zhao; William S Pearson; Simon Capewell
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

8.  Predicting the 30-year risk of cardiovascular disease: the framingham heart study.

Authors:  Michael J Pencina; Ralph B D'Agostino; Martin G Larson; Joseph M Massaro; Ramachandran S Vasan
Journal:  Circulation       Date:  2009-06-08       Impact factor: 29.690

9.  Treatment of hypertension in patients 80 years of age or older.

Authors:  Nigel S Beckett; Ruth Peters; Astrid E Fletcher; Jan A Staessen; Lisheng Liu; Dan Dumitrascu; Vassil Stoyanovsky; Riitta L Antikainen; Yuri Nikitin; Craig Anderson; Alli Belhani; Françoise Forette; Chakravarthi Rajkumar; Lutgarde Thijs; Winston Banya; Christopher J Bulpitt
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

10.  Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

Authors:  Nanette K Wenger; Sandra J Lewis; David M Herrington; Vera Bittner; Francine K Welty
Journal:  Ann Intern Med       Date:  2007-07-03       Impact factor: 25.391

View more
  1 in total

1.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.